Research programme: age-related macular degeneration stem cell therapies - Sumitomo/Healios

Drug Profile

Research programme: age-related macular degeneration stem cell therapies - Sumitomo/Healios

Alternative Names: HLCR 011; Induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) cell therapy - Healios/Sumitomo Dainippon Pharma; iPSC-derived RPE cell therapy - Healios/Sumitomo Dainippon Pharma

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma; Healios
  • Developer Healios; National Eye Institute; SighRegen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 27 Jul 2018 Sumitomo Dainippon Pharma plans a clinical trial of HLCR 011 for Age-related macular degeneration in Japan (Sumitomo Dainippon Pharma pipeline, August 2018).
  • 24 May 2018 Healios establishes CRADA with National Eye Institute for the development of iPSC-derived RPE therapy in Age-related macular degeneration in USA
  • 24 May 2018 Preclinical trials in Age-related macular degeneration in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top